Myriad Genetics, Inc. (MYGN) Tops Q1 EPS by 1c, Reaffirms FY12 Guidance
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $3.89 -6.04%
Revenue Growth %: -7.0%
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -7.0%
Financial Fact:
Research and development expense: 19.4M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Myriad Genetics, Inc. (NASDAQ: MYGN) reported Q1 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $110.5 million versus the consensus estimate of $106.49 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Myriad Genetics promotes Vishal Sikri to EVP of commercial
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
- Kroger (KR) Tops Q2 EPS by 3c, Misses on Revenue; Offers FY27 EPS Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
